
|Videos|March 28, 2019
Dr. Fleming Shares Encouraging Data With Antiandrogen Therapies in Prostate Cancer
Author(s)Mark T. Fleming, MD
Mark T. Fleming, MD, medical oncologist, Virginia Oncology Associates, The US Oncology Research, discusses exciting data seen with antiandrogen agents for the treatment of prostate cancer.
Advertisement
Mark T. Fleming, MD, medical oncologist, Virginia Oncology Associates, The US Oncology Research, discusses exciting data seen with antiandrogen agents for the treatment of prostate cancer.
Darolutamide, enzalutamide (Xtandi), and apalutamide (Erleada) have all demonstrated promising findings, signifying that therapies are moving forward in this space. It is exciting to see that patients now have a lot of options, Fleming says.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5




















